PacBio

PacBio
Name	Pacific Biosciences
Trade name	PacBio
Industry	Biotechnology
Founded	2004
Founder	Craig Venter; Steve Turner; Lee Hood; Jonas Korlach
Headquarters	Menlo Park, California
Products	Single Molecule, Real-Time sequencing; Sequel; Sequel II; SMRT Cells
Revenue	(varies)
Website	(official)

PacBio

PacBio is a biotechnology company known for its single-molecule, long-read DNA sequencing platforms. Founded in the early 21st century, the company developed Single Molecule, Real-Time sequencing to address limits of short-read technologies and to enable de novo assembly, structural-variation detection, and full-length transcript analysis. Its platforms have been used in genomics projects involving model organisms, clinical cohorts, agricultural genetics, and evolutionary studies.

Overview

PacBio produces instruments and consumables designed for long-read sequencing, competing in a commercial and academic marketplace alongside firms, institutes, and consortia. The company’s platforms are implemented in laboratories at universities such as Harvard University, Stanford University, University of California, Berkeley, and facilities like the Broad Institute and the Wellcome Sanger Institute. Funding, partnerships, and collaborations have included venture investors, government agencies such as the National Institutes of Health, and biotechnology corporations including Roche and Illumina-related consortia in comparative benchmarking efforts. PacBio systems support projects tied to large-scale efforts such as the Human Genome Project-era initiatives, population genomics studies like the 1000 Genomes Project, and biodiversity programs connected to museums and botanical gardens.

Technology and platform

PacBio’s core technology is Single Molecule, Real-Time (SMRT) sequencing, which relies on zero-mode waveguides and real-time observation of DNA synthesis. The platform integrates optics, biochemistry, and informatics from teams with backgrounds in molecular biology laboratories, physics departments, and instrumentation groups affiliated with institutions like the Salk Institute and the California Institute of Technology. SMRT chemistry uses DNA polymerases tethered in nanophotonic wells to incorporate labeled nucleotides; signal detection is linked to optical hardware and algorithms developed by computational groups in centers such as the European Bioinformatics Institute and the National Center for Biotechnology Information. Instruments like the Sequel and Sequel II systems increased throughput per run by improving SMRT Cell density and polymerase kinetics, while consumables include barcoding kits and long-insert library prep tools used in clinical centers such as Mayo Clinic and agricultural research stations affiliated with the United States Department of Agriculture.

Applications

PacBio sequencing is applied across human genetics, microbial genomics, plant and animal breeding, and metagenomics. In human genomics, SMRT reads have been used in rare-disease diagnostics at hospitals such as Johns Hopkins Hospital and in cancer genomics projects at institutions including Memorial Sloan Kettering Cancer Center. Population-scale efforts and haplotype phasing studies leverage long reads in centers participating in initiatives like the All of Us Research Program and national biobanks exemplified by the UK Biobank. In agriculture, breeding programs at universities such as Cornell University and companies including Bayer rely on long-read assemblies for structural-variant discovery. Microbial and metagenomic applications include pathogen surveillance carried out by public-health agencies like the Centers for Disease Control and Prevention and environmental genomics work coordinated with the Smithsonian Institution.

Performance and comparison

PacBio’s long reads contrast with short-read platforms produced by firms such as Illumina and single-molecule technologies from rivals like Oxford Nanopore Technologies. Compared to short-read sequencing used in consortia such as the 1000 Genomes Project and clinical sequencing initiatives at institutions like Broad Institute, SMRT reads typically provide improved contiguity for de novo assemblies and superior resolution of repetitive regions referenced in publications from labs at Max Planck Society and the European Molecular Biology Laboratory. Recent chemistry and instrument iterations aim to reduce per-base error rates and increase yield to meet standards adopted by clinical laboratories like Genomics England and accreditation bodies. Benchmarking exercises organized by scientific societies and reference centers associated with National Human Genome Research Institute reveal trade-offs among read length, accuracy, cost per gigabase, and throughput when comparing PacBio to other platforms.

History and company

The company was established by scientists and entrepreneurs with ties to sequencing pioneers and research institutions, drawing on expertise from laboratories at institutions such as Institute for Systems Biology and biotech startups founded in the late 1990s and early 2000s. Over time, PacBio advanced through rounds of financing involving venture firms, collaborations with corporations like Roche, and public offerings that placed it among publicly traded biotechnology companies. Strategic partnerships have included reagent suppliers, computational genomics providers, and contract research organizations serving pharmaceutical companies such as Pfizer and agricultural corporations. Key milestones include commercial launches of early instruments, the introduction of Sequel systems, and iterative chemistry upgrades that responded to challenges faced by diagnostic laboratories and academic sequencing centers.

Limitations and challenges

Limitations of PacBio technology have included higher instrument and per-run costs relative to some short-read options used by core facilities at universities and contract sequencing providers, throughput constraints for large-scale population sequencing performed by national biobanks, and biochemical challenges that affect read-length distribution and polymerase performance. Error profiles, while improving, historically required specialized consensus algorithms developed by bioinformatics groups at institutions such as University of Washington and companies like Google’s genomics efforts to achieve high consensus accuracy. Adoption barriers include capital investment demands for clinical laboratories, regulatory pathways overseen by agencies such as the Food and Drug Administration, and competition from alternative long-read vendors and evolving short-read workflows used by clinical and research consortia.

Category:Biotechnology companies